Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA.

J Control Release. 2013 Dec 28;172(3):625-33. doi: 10.1016/j.jconrel.2013.10.008.

2.

Honokiol inhibits pathological retinal neovascularization in oxygen-induced retinopathy mouse model.

Vavilala DT, O'Bryhim BE, Ponnaluri VK, White RS, Radel J, Symons RC, Mukherji M.

Biochem Biophys Res Commun. 2013 Sep 6;438(4):697-702. doi: 10.1016/j.bbrc.2013.07.118.

PMID:
23921228
3.

Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A.

Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, Shen J, Iwase T, Tian J, Stevens R, Hackett SF, Stumpp MT, Campochiaro PA.

Angiogenesis. 2014 Jul;17(3):553-62. doi: 10.1007/s10456-013-9402-5.

4.

Beta-lapachone inhibits pathological retinal neovascularization in oxygen-induced retinopathy via regulation of HIF-1α.

Park SW, Kim JH, Kim KE, Jeong MH, Park H, Park B, Suh YG, Park WJ, Kim JH.

J Cell Mol Med. 2014 May;18(5):875-84. doi: 10.1111/jcmm.12235.

5.

Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Hou H, Nieto A, Ma F, Freeman WR, Sailor MJ, Cheng L.

J Control Release. 2014 Mar 28;178:46-54. doi: 10.1016/j.jconrel.2014.01.003.

6.

Agents that bind annexin A2 suppress ocular neovascularization.

Lima e Silva R, Shen J, Gong YY, Seidel CP, Hackett SF, Kesavan K, Jacoby DB, Campochiaro PA.

J Cell Physiol. 2010 Nov;225(3):855-64. doi: 10.1002/jcp.22296.

7.

Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.

Alikacem N, Yoshizawa T, Nelson KD, Wilson CA.

Invest Ophthalmol Vis Sci. 2000 May;41(6):1561-9.

PMID:
10798677
8.

Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Chhablani J, Nieto A, Hou H, Wu EC, Freeman WR, Sailor MJ, Cheng L.

Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):1268-79. doi: 10.1167/iovs.12-11172.

9.

Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization.

Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX.

J Pharmacol Exp Ther. 2012 Jul;342(1):131-9. doi: 10.1124/jpet.112.192575.

10.

Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.

Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T, Campochiaro PA.

FASEB J. 2003 May;17(8):896-8.

11.

Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells.

Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, Shaw GC, Usui S, Wang Y, Zack DJ, Campochiaro PA.

J Cell Physiol. 2010 Jul;224(1):262-72. doi: 10.1002/jcp.22129.

12.

Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization.

Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA.

FASEB J. 2010 Jun;24(6):1759-67. doi: 10.1096/fj.09-145664.

13.

Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF.

Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, Li Y.

J Cell Physiol. 2009 Jan;218(1):66-74. doi: 10.1002/jcp.21566.

PMID:
18767037
14.

pH-responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics.

Schoener CA, Hutson HN, Peppas NA.

J Biomed Mater Res A. 2013 Aug;101(8):2229-36. doi: 10.1002/jbm.a.34532.

15.

Role of hypoxia-inducible factor-1α and survivin in oxygen-induced retinopathy in mice.

Liu N, Sun Y, Zhao N, Chen L.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6814-9.

16.

Inhibitory effect of Samul-tang on retinal neovascularization in oxygen-induced retinopathy.

Lee YM, Kim CS, Jo K, Sohn EJ, Kim JS, Kim J.

BMC Complement Altern Med. 2015 Aug 12;15:271. doi: 10.1186/s12906-015-0800-7.

17.

Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy.

Zhang Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, Wang L.

Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):919-27. doi: 10.1007/s00417-009-1066-x.

PMID:
19301028
18.

Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.

Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J.

Mol Vis. 2004 Dec 22;10:964-72.

20.

Design of tumor-homing and pH-responsive polypeptide-doxorubicin nanoparticles with enhanced anticancer efficacy and reduced side effects.

Hu J, Xie L, Zhao W, Sun M, Liu X, Gao W.

Chem Commun (Camb). 2015 Jul 21;51(57):11405-8. doi: 10.1039/c5cc04035c.

PMID:
26086450
Items per page

Supplemental Content

Support Center